Alliancebernstein L.P. Neoleukin Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.25 $20,700 - $50,625	-22,500 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.72 - $5.23 $4,472 - $13,598	-2,600 Reduced 10.36%	22,500 $42,000
Q4 2021 Feb 14, 2022	SELL	$4.65 - $7.75 $6,045 - $10,075	-1,300 Reduced 4.92%	25,100 $121,000
Q2 2021 Jul 30, 2021	BUY	$9.23 - $13.12 $38,766 - $55,104	4,200 Added 18.92%	26,400 $244,000
Q1 2021 May 06, 2021	SELL	$11.26 - $15.78 $25,898 - $36,294	-2,300 Reduced 9.39%	22,200 $273,000
Q3 2020 Nov 12, 2020	BUY	$9.68 - $17.01 $54,208 - $95,256	5,600 Added 29.63%	24,500 $294,000
Q2 2020 Aug 13, 2020	BUY	$9.95 - $17.05 $188,055 - $322,245	18,900 New	18,900 $314,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.